Amgen Inc. $AMGN is Hofer & Associates. Inc’s 5th Largest Position

Hofer & Associates. Inc boosted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 111.4% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 27,140 shares of the medical research company’s stock after acquiring an additional 14,302 shares during the period. Amgen comprises 4.7% of Hofer & Associates. Inc’s investment portfolio, making the stock its 5th biggest holding. Hofer & Associates. Inc’s holdings in Amgen were worth $8,883,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Board of the Pension Protection Fund purchased a new stake in shares of Amgen during the 4th quarter worth $26,000. Olistico Wealth LLC acquired a new position in shares of Amgen during the fourth quarter worth $33,000. Holos Integrated Wealth LLC acquired a new stake in Amgen in the fourth quarter valued at $37,000. Howard Hughes Medical Institute acquired a new stake in Amgen in the second quarter valued at $32,000. Finally, Cloud Capital Management LLC purchased a new stake in Amgen during the 3rd quarter worth about $34,000. 76.50% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

AMGN has been the subject of several analyst reports. Oppenheimer set a $400.00 price objective on Amgen and gave the stock an “outperform” rating in a research report on Thursday, January 29th. Piper Sandler raised their target price on Amgen from $381.00 to $432.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 18th. UBS Group boosted their target price on Amgen from $380.00 to $390.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Wells Fargo & Company upped their price target on Amgen from $375.00 to $390.00 and gave the company an “equal weight” rating in a report on Thursday, March 19th. Finally, Guggenheim increased their price target on shares of Amgen from $305.00 to $347.00 and gave the company a “neutral” rating in a research note on Friday, February 6th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, thirteen have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $354.60.

Amgen Stock Performance

Shares of AMGN stock opened at $349.00 on Tuesday. The stock’s 50-day moving average is $362.96 and its two-hundred day moving average is $331.05. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. Amgen Inc. has a 1 year low of $261.43 and a 1 year high of $391.29. The firm has a market cap of $188.14 billion, a price-to-earnings ratio of 24.53, a PEG ratio of 3.46 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. The firm had revenue of $9.87 billion during the quarter, compared to analysts’ expectations of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The business’s revenue was up 8.6% on a year-over-year basis. During the same period in the prior year, the firm earned $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Analysts predict that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be issued a $2.52 dividend. This represents a $10.08 annualized dividend and a dividend yield of 2.9%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s dividend payout ratio is presently 70.84%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.